Health

For patients facing metastatic colorectal cancer (mCRC), the landscape of treatment options can feel complex. While several therapies exist, particularly in the later lines of treatment, the most effective approach isn’t one-size-fits-all. Increasingly, oncologists are focusing on a collaborative decision-making process, balancing clinical data with individual patient priorities, according to experts in the field. Understanding the nuances of available treatments – including trifluridine/tipiracil (Lonsurf) plus bevacizumab (Avastin), and fruquintinib (Fruzaqla) – is crucial for both patients and their care teams.

The goal in later-line mCRC treatment is often to maximize disease control and progression-free survival (PFS), but the path to achieving that goal is individualized. Factors like a patient’s overall health, treatment preferences, and specific disease characteristics all play a role. Recent advances have provided clinicians with more tools to manage the disease, but selecting the right combination requires careful consideration. Effective treatment for metastatic colorectal cancer requires a strategy that balances efficacy data with individual patient priorities.

Understanding the Current Treatment Landscape

Trifluridine/tipiracil and bevacizumab have become a cornerstone of treatment for mCRC that has progressed after initial therapies. Data from the phase 3 SUNLIGHT trial (NCT04737187) supports the use of this combination for patients aiming to maintain a PFS of at least four months. This approach focuses on stabilizing the disease and extending the time before it progresses. The trial demonstrated promising results in disease control, offering a valuable option for many patients.

Fruquintinib, offers a different advantage: convenience. Administered orally, it provides an alternative for patients who wish to avoid intravenous infusions. However, its use requires careful consideration of a patient’s baseline physiological factors. Specifically, a platelet count of at least 70,000 is generally recommended before initiating fruquintinib, as the medication can potentially lower platelet levels.

Balancing Efficacy and Side Effects

While maximizing disease control is paramount, managing treatment-related side effects is equally important. The SUNLIGHT trial offered reassuring data regarding the safety profile of trifluridine/tipiracil plus bevacizumab. Researchers found that rates of febrile neutropenia – a serious infection risk associated with low white blood cell counts – were low in patients receiving this combination. “Really patients had an outside the bone marrow suppression and low rates of severe toxicities,” noted an expert in the field. The availability of growth factor support (G-CSF) can further help mitigate potential bone marrow suppression, allowing patients to continue treatment even if their white blood cell counts temporarily decrease.

It’s important to remember that experiencing a low white blood cell count doesn’t automatically translate to feeling unwell. Many patients may not experience significant fatigue or other noticeable symptoms. Open communication with the oncology team is crucial for monitoring side effects and adjusting treatment as needed.

The Importance of Individualized Treatment Plans

The decision of which treatment path to pursue is deeply personal. Some patients prioritize minimizing trips to the clinic and prefer the convenience of an oral medication like fruquintinib. Others may prioritize maximizing disease control, even if it means continuing with intravenous infusions. “It’s individualized and a patient discussion, and the physicians who know their patients best and have been treating them through that journey will be able to guide them to the best approach,” explained a leading oncologist.

Factors beyond clinical data also come into play. A patient’s lifestyle, support system, and personal values all contribute to their overall treatment goals. A thorough discussion with the oncology team, including a frank assessment of potential benefits and risks, is essential for making an informed decision.

Looking Ahead

Ongoing research continues to refine our understanding of mCRC and identify new treatment strategies. As more data emerges from clinical trials, oncologists will have even more tools at their disposal to personalize treatment plans and improve outcomes for patients. The focus remains on optimizing disease control, minimizing side effects, and enhancing the quality of life for individuals living with this challenging disease.

What questions do you have about metastatic colorectal cancer treatment options? Share your thoughts in the comments below, and please consider sharing this article with others who may find it helpful.

Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. We see essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.

California health officials are monitoring an increase in human metapneumovirus (HMPV), a common respiratory virus, detected in wastewater across several communities. While the rise is notable, experts emphasize there’s no cause for widespread alarm, particularly as immunity levels have begun to recover following the disruptions of the COVID-19 pandemic. The virus, which doesn’t have a specific vaccine or treatment, is currently being observed at varying levels throughout the state, with higher concentrations reported in Northern California.

Data from the WastewaterScan Dashboard, a public database tracking infectious diseases through sewage monitoring, indicates a majority of Northern California communities are experiencing high levels of HMPV. A Los Angeles Times analysis further pinpointed increases in HMPV levels in Merced, located in the San Joaquin Valley and the Bay Area cities of Novato and Sunnyvale between mid-December and the complete of February. Los Angeles County has similarly detected the virus, though currently at low to moderate levels. Understanding this resurgence of HMPV is key, as it signals a potential return to pre-pandemic patterns of seasonal respiratory illnesses.

What is Human Metapneumovirus?

First identified in 2001, according to the U.S. Centers for Disease Control and Prevention, HMPV is transmitted through close contact with infected individuals or by touching contaminated surfaces. Dr. Neha Nanda, chief of infectious diseases and hospital epidemiologist for Keck Medicine of USC, explained the transmission pathways. Like influenza, HMPV thrives and spreads more easily in colder temperatures, infectious disease experts note. Typically, HMPV cases begin appearing in January, peaking in March or April, and declining by June, as observed by Dr. Jessica August, chief of infectious diseases at Kaiser Permanente Santa Rosa.

Why the Recent Increase?

Prior to the 2020 pandemic, regular seasonal exposure to viruses like HMPV helped build a degree of natural immunity within the population. This immunity waned as public health measures – such as social distancing and mask-wearing – reduced transmission. As people resumed normal activities, they became more susceptible to the virus. Notably, there is currently no vaccine available for human metapneumovirus. “That’s why after the pandemic we saw record-breaking childhood viral illnesses because we lacked the usual immunity that we had, just from lack of exposure,” Dr. August said. “All of that also led to longer viral seasons, more severe illness. But all of these things have settled down in many respects.”

National surveillance data reflects this trend. In 2024, the national test positivity rate for HMPV peaked at 11.7% at the end of March, according to the National Respiratory and Enteric Virus Surveillance System. The following year saw a peak of 7.15% in late April. As of February 21, 2026 – the most recent date with complete data – the highest test positivity rate recorded this year was 6.1%.

Symptoms and Treatment

Most individuals infected with HMPV experience mild, cold-like symptoms, including cough, fever, nasal congestion, and sore throat, and may not require medical attention. However, the infection can progress to more serious conditions, such as asthma attacks, reactive airway disease (wheezing and difficulty breathing), middle ear infections, croup (characterized by a “barking” cough), bronchitis, and even pneumonia. Individuals who are immunocompromised or have underlying medical conditions, as well as young children and older adults, are at higher risk of developing severe illness, Dr. Nanda cautioned.

Currently, there is no specific treatment protocol or antiviral medication for HMPV. Treatment typically focuses on managing symptoms, with recommendations for rest and increased fluid intake, according to the American Lung Association. If symptoms worsen, seeking medical advice is recommended.

Preventing HMPV Spread

Preventing the spread of HMPV involves similar measures used to prevent other respiratory illnesses. The American Lung Association recommends frequent handwashing with soap and water (or using an alcohol-based hand sanitizer when soap and water aren’t available), cleaning frequently touched surfaces, improving air circulation in crowded spaces, avoiding close contact with sick individuals, and avoiding touching the eyes, nose, and mouth.

As we move forward, continued monitoring of HMPV and other respiratory viruses will be crucial. Increased awareness and adherence to preventative measures can assist mitigate the impact of these illnesses on public health. The resurgence of HMPV serves as a reminder of the ongoing need for vigilance and proactive health practices.

What are your thoughts on the rise of respiratory viruses? Share your comments below, and please share this article with your network to help spread awareness.

Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. This proves essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.